Last conference call Nader speculated that a buy o
Post# of 153887
(Total Views: 935)
Posted On: 09/21/2020 12:21:28 AM
Re: ClosetInvestor #57129
Last conference call Nader speculated that a buy out would be difficult but would be way more than IMMU. He stated that he sees a buy out by indications. Could you imagine? That is a very nice way to consider selling by indication and not all at once.
It goes with Naders estimate that Cytodyn is a triple digit value currently in his opinion. I like that his opinion of the stock is so high. It means to me that nobody is willing to pay what Nader believes. Hence we won’t be bought out. You know he won’t even consider an offer unless it is triple digit the way he talks about our value.
I don’t want to see a buy out anyway. I would like to see this company grow and watch the acceleration of indications progress to approval. Once one is approved and the safety is addressed then the other indications can use that same safety record and do small phase 2 trials for proof of concept and quick phase 3 trials to prove efficacy in that indication. Then we can maybe reach those quadruple digit stock price that Nader once mentioned a while back.
We have some pretty big blockbuster indications for Leronlimab and it’s not unfathomable to achieve high triple digit or quadruple digit stock prices. With this much potential. How could we sell for pennies when time will prove the value of this stock. I am hoping 3-5 years down the road we are at those high triple digit stock prices and see no reason we are not.
I can’t see a quick dollar return when huge potential is not that far away. 5 years is just a small click in time. The older I get the fast time seems to roll. Who doesn’t have 5 years to get filthy rich at quadruple stock price?
It goes with Naders estimate that Cytodyn is a triple digit value currently in his opinion. I like that his opinion of the stock is so high. It means to me that nobody is willing to pay what Nader believes. Hence we won’t be bought out. You know he won’t even consider an offer unless it is triple digit the way he talks about our value.
I don’t want to see a buy out anyway. I would like to see this company grow and watch the acceleration of indications progress to approval. Once one is approved and the safety is addressed then the other indications can use that same safety record and do small phase 2 trials for proof of concept and quick phase 3 trials to prove efficacy in that indication. Then we can maybe reach those quadruple digit stock price that Nader once mentioned a while back.
We have some pretty big blockbuster indications for Leronlimab and it’s not unfathomable to achieve high triple digit or quadruple digit stock prices. With this much potential. How could we sell for pennies when time will prove the value of this stock. I am hoping 3-5 years down the road we are at those high triple digit stock prices and see no reason we are not.
I can’t see a quick dollar return when huge potential is not that far away. 5 years is just a small click in time. The older I get the fast time seems to roll. Who doesn’t have 5 years to get filthy rich at quadruple stock price?
(11)
(0)